Korsana Biosciences closed a $175 million financing to advance a preclinical Alzheimer’s program that uses a platform to ferry antibodies across the blood‑brain barrier. The company said the capital will fund lead candidate development and IND‑enabling studies targeting central nervous system delivery. The raise positions Korsana alongside larger rivals exploring BBB transport strategies—Roche and AbbVie have clinical‑stage programs with similar penetration approaches—potentially accelerating competition for brain‑targeting biologics and partner interest.